Evidence map›Paper›PMID 27508046›Full record

ArticleAmerican journal of translational research2016

Therapeutic effects of human umbilical cord mesenchymal stem cells transplantation on hypoxic ischemic encephalopathy.

Bingchuan Xie, Ping Gu, Wenting Wang, Ci Dong, Lina Zhang, Jun Zhang, Huimiao Liu, Fucheng Qiu, Rui Han, Zhenqing Zhang and 1 more

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Autologous cord blood in children with cerebral palsy: a review.International journal of molecular sciences · 2019
    Review
  17. Article
  18. Article
  19. Article
  20. Aquaporin-4: A Potential Therapeutic Target for Cerebral Edema.International journal of molecular sciences · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Bingchuan XieDepartment of Gerontology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China; Department of Neurology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China.
Ping GuDepartment of Gerontology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China; Department of Neurology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China; Brain Aging and Cognitive, Neuroscience Laboratory of Hebei ProvinceShijiazhuang 050031, China.
Wenting WangDepartment of Gerontology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China; Department of Neurology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China.
Ci DongDepartment of Gerontology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China; Department of Neurology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China.
Lina ZhangDepartment of Gerontology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China; Department of Neurology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China.
Jun ZhangThe Lab of Cell Therapy, The First Hospital of Hebei Medical University Shijiazhuang 050031, China.
Huimiao LiuDepartment of Gerontology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China; Department of Neurology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China.
Fucheng QiuDepartment of Gerontology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China; Department of Neurology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China.
Rui HanDepartment of Gerontology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China; Department of Neurology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China.
Zhenqing ZhangDepartment of Gerontology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China; Department of Neurology, The First Hospital of Hebei Medical UniversityShijiazhuang 050031, China.
Baoyong YanBrain Aging and Cognitive, Neuroscience Laboratory of Hebei Province Shijiazhuang 050031, China.
Hebei Medical University · CNHBIS (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHuman umbilical cord mesenchymal stem cells (hUC-MSCs) hold substantial promise for the treatment of ischemic neurological disease, but few clinical data are currently available about its therapeutic effects in hypoxic ischemic encephalopathy (HIE). This study is to evaluate the effects of hUC-MSCs transplantation on patients with HIE. Methods A total 22 patients with HIEwere randomly divided into hUC-MSCs transplantation group (n = 12) and control group (n = 10). After isolation, hUC-MSCs were cultured for 3 to 5 passages in vitro and then intravenously administered to HIE patients in the transplantation group, while the control group received routine treatment only. The outcomes of HIE patients were evaluated at designated time points by clinical assessment scales, including NIHSS, Barthel Index, MMSE, HAMA24, HAMD14 and UPDRS.

resultshUC-MSCs were identified by morphological analysis and flow cytometry assays before clinic transplantation. No significant differences of demographic characteristics were observed between the two groups of subjects. Compared to the control group, hUC-MSCs transplantation markedly improved the outcomes of HIE patients leading to better recovery of neurological function, cognition ability, emotional reaction and extrapyramidal function. No significant adverse effects were found in subjects with hUC-MSCs transplantation during a 180-day follow-up period.

conclusionThese data suggest that hUC-MSCs therapy markedly improves the outcomes of patients with HIE, which is potential for the routine treatment of ischemic neurological disease.

Indexed as

Human umbilical cord mesenchymal stem cellshypoxic-ischemic encephalopathytransplantation

Identifiers

PMID27508046
PMCPMC4969462
OpenAlexW2515186888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.